TrialBritish journal of haematology2024

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia.

Jaimal Kothari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.